This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
5-Hydroxytryptophan: Difference between revisions
>Tracer Removed Category:Psychoactive substance. Added Category:Amino acid |
>Eggcooker m Added "Depth perception distortions" (mine 700mg experience) |
||
| Line 17: | Line 17: | ||
The psychoactive action of 5-HTP is derived from its increase in production of [[serotonin]] in central nervous system tissue. 5-HTP is decarboxylated to serotonin (5-hydroxytryptamine or 5-HT) by the enzyme 'aromatic-L-amino-acid decarboxylase', with the help of vitamin B<sub>6</sub>.<ref>https://www.ncbi.nlm.nih.gov/pubmed/6983619 | Effect of pyridoxal phosphate deficiency on aromatic L-amino acid decarboxylase activity with L-DOPA and L-5-hydroxytryptophan as substrates in rats.</ref> This reaction occurs both in nervous tissue and in the liver.<ref>https://www.ncbi.nlm.nih.gov/pubmed/6974228 | Characteristics of dihydroxyphenylalanine/5-hydroxytryptophan decarboxylase activity in brain and liver of cat.</ref> 5-HTP crosses the blood–brain barrier, while 5-HT (serotonin) does not.<ref>https://www.ncbi.nlm.nih.gov/pubmed/18445233 | Augmented brain 5-HT crosses the blood-brain barrier through the 5-HT transporter in rat.</ref> | The psychoactive action of 5-HTP is derived from its increase in production of [[serotonin]] in central nervous system tissue. 5-HTP is decarboxylated to serotonin (5-hydroxytryptamine or 5-HT) by the enzyme 'aromatic-L-amino-acid decarboxylase', with the help of vitamin B<sub>6</sub>.<ref>https://www.ncbi.nlm.nih.gov/pubmed/6983619 | Effect of pyridoxal phosphate deficiency on aromatic L-amino acid decarboxylase activity with L-DOPA and L-5-hydroxytryptophan as substrates in rats.</ref> This reaction occurs both in nervous tissue and in the liver.<ref>https://www.ncbi.nlm.nih.gov/pubmed/6974228 | Characteristics of dihydroxyphenylalanine/5-hydroxytryptophan decarboxylase activity in brain and liver of cat.</ref> 5-HTP crosses the blood–brain barrier, while 5-HT (serotonin) does not.<ref>https://www.ncbi.nlm.nih.gov/pubmed/18445233 | Augmented brain 5-HT crosses the blood-brain barrier through the 5-HT transporter in rat.</ref> | ||
Excess 5-HTP, especially when administered with vitamin B<sub>6</sub>, is thought to be metabolized and excreted.<ref>Biochemical properties and kinetic parameters of dihydroxyphenylalanine--5-hydroxytryptophan decarboxylase in brain, liver, and adrenals of cat | doi=10.1139/o79-126}}</ref><ref>https://www.ncbi.nlm.nih.gov/pubmed/1088369 | On the tryptophan-serotonin metabolism in manic-depressive disorders. Changes in plasma 5-HT and 5-HIAA levels and urinary 5-HIAA excretion following oral loading of L-5HTP in patients with depression</ref> | Excess 5-HTP, especially when administered with vitamin B<sub>6</sub>, is thought to be metabolized and excreted.<ref><nowiki>Biochemical properties and kinetic parameters of dihydroxyphenylalanine--5-hydroxytryptophan decarboxylase in brain, liver, and adrenals of cat | doi=10.1139/o79-126}}</nowiki></ref><ref>https://www.ncbi.nlm.nih.gov/pubmed/1088369 | On the tryptophan-serotonin metabolism in manic-depressive disorders. Changes in plasma 5-HT and 5-HIAA levels and urinary 5-HIAA excretion following oral loading of L-5HTP in patients with depression</ref> | ||
==Subjective effects== | ==Subjective effects== | ||
| Line 47: | Line 47: | ||
*'''[[Effect::Color enhancement]]''' | *'''[[Effect::Color enhancement]]''' | ||
*'''[[Effect::Drifting]]''' | *'''[[Effect::Drifting]]''' | ||
*'''[[Effect::Depth perception distortions]]''' | |||
}} | }} | ||
| Line 76: | Line 77: | ||
Additional experience reports can be found here: | Additional experience reports can be found here: | ||
* [https://www.erowid.org/experiences/subs/exp_Tryptophan_5HTP.shtml Erowid Experience Vaults: 5-HTP] | *[https://www.erowid.org/experiences/subs/exp_Tryptophan_5HTP.shtml Erowid Experience Vaults: 5-HTP] | ||
==Toxicity and harm potential== | ==Toxicity and harm potential== | ||
| Line 86: | Line 87: | ||
Combinations in the list below may increase the amount of neurotransmitters, such as serotonin, to dangerous or even fatal levels, resulting in life-threatening [[serotonin syndrome]]. | Combinations in the list below may increase the amount of neurotransmitters, such as serotonin, to dangerous or even fatal levels, resulting in life-threatening [[serotonin syndrome]]. | ||
*'''[[DangerousInteraction::Selective serotonin re-uptake inhibitors]] (SSRIs)''' - When combined with antidepressants of the SSRI class, high doses of 5-HTP can cause acute serotonin syndrome in rats.<ref name="one">https://www.ncbi.nlm.nih.gov/pubmed/18499101 | Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats.</ref><ref name="two">https://www.ncbi.nlm.nih.gov/pubmed/16488409 | Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats.</ref> | *'''[[DangerousInteraction::Selective serotonin re-uptake inhibitors]] (SSRIs)''' - When combined with antidepressants of the SSRI class, high doses of 5-HTP can cause acute serotonin syndrome in rats.<ref name="one">https://www.ncbi.nlm.nih.gov/pubmed/18499101 | Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats.</ref><ref name="two">https://www.ncbi.nlm.nih.gov/pubmed/16488409 | Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats.</ref> | ||
*'''[[Serotonin-norepinephrine reuptake inhibitors]] (SNRIs)''' | *'''[[Serotonin-norepinephrine reuptake inhibitors]] (SNRIs)''' | ||
*'''[[DangerousInteraction::Serotonin releasers]]''' such as '''[[MDMA]]''', '''[[4-FA]]''', '''[[MDAI]]''' and '''[[αMT]]''' - To prevent serotonin syndrome, 5-HTP should only be taken once the user has come down from the MDMA (or other serotonin releaser), roughly 12 hours after the last dose. | *'''[[DangerousInteraction::Serotonin releasers]]''' such as '''[[MDMA]]''', '''[[4-FA]]''', '''[[MDAI]]''' and '''[[αMT]]''' - To prevent serotonin syndrome, 5-HTP should only be taken once the user has come down from the MDMA (or other serotonin releaser), roughly 12 hours after the last dose. | ||
*'''[[DangerousInteraction::MAOIs]]''' such as '''[[syrian rue]]''', '''[[banisteriopsis caapi]]''', '''[[2C-T-2]]''', '''[[2C-T-7]]''', '''[[αMT]]''', and some '''[[antidepressants]]''' - When combined with antidepressants of the MAOI class, high doses of 5-HTP can cause acute serotonin syndrome in rats.<ref name="one" /><ref name="two" /> | *'''[[DangerousInteraction::MAOIs]]''' such as '''[[syrian rue]]''', '''[[banisteriopsis caapi]]''', '''[[2C-T-2]]''', '''[[2C-T-7]]''', '''[[αMT]]''', and some '''[[antidepressants]]''' - When combined with antidepressants of the MAOI class, high doses of 5-HTP can cause acute serotonin syndrome in rats.<ref name="one" /><ref name="two" /> | ||
*'''[[DangerousInteraction::Tricyclic antidepressants]] (TCAs)''' | *'''[[DangerousInteraction::Tricyclic antidepressants]] (TCAs)''' | ||
*'''[[DangerousInteraction::Tramadol]]''' | *'''[[DangerousInteraction::Tramadol]]''' | ||
| Line 99: | Line 101: | ||
==See also== | ==See also== | ||
*[[Serotonin syndrome]] | *[[Serotonin syndrome]] | ||
*[[Tryptamine]] | *[[Tryptamine]] | ||
*[[Neurotransmitter]] | *[[Neurotransmitter]] | ||
*[[MDMA]] | *[[MDMA]] | ||
*[[MDAI]] | *[[MDAI]] | ||
| Line 107: | Line 110: | ||
==External links== | ==External links== | ||
*[https://en.wikipedia.org/wiki/5-Hydroxytryptophan 5-Hydroxytryptophan (Wikipedia)] | *[https://en.wikipedia.org/wiki/5-Hydroxytryptophan 5-Hydroxytryptophan (Wikipedia)] | ||
*[https://isomerdesign.com/PiHKAL/explore.php?id=5149 5-Hydroxytryptophan (Isomer Design)] | *[https://isomerdesign.com/PiHKAL/explore.php?id=5149 5-Hydroxytryptophan (Isomer Design)] | ||
| Line 114: | Line 118: | ||
==References== | ==References== | ||
<references/> | <references /> | ||
[[Category:Amino acid]] | [[Category:Amino acid]] | ||
[[Category:Tryptamine]] | [[Category:Tryptamine]] | ||
[[Category:Antidepressant]] | [[Category:Antidepressant]] | ||
[[Category:Precursor]] | [[Category:Precursor]] | ||